Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study
Lei-Po Lin, Jia-Yong Su, Xiao-Feng Dong, Fuquan Yang et autres
BACKGROUND AND AIMS: The role of adjuvant programmed cell death-1 (PD-1) inhibitors following curative hepatectomy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence remains controversial. This study aims to evaluate the efficacy and safety of camrelizumab (a PD-1 inhibitor) …
cn (code pays fourni par la source)
0 citations
European Journal of Gastroenterology & Hepatology